Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 132

Moghimi, S. M. and J. Szebeni (2003) Stealth liposomes and long circulating nanoparticles:
Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog
Lipid Res 42 (6):463-478.
Monteiro-Riviere, N. A., K. Wiench, R. Landsiedel, S. Schulte, A. O. Inman, and J. E. Riviere
(2011) Safety evaluation of sunscreen formulations containing titanium dioxide and
zinc oxide nanoparticles in UVB sunburned skin: An in vitro and in vivo study. Toxicol
Sci 123 (1):264-280.
Moschwitzer, J. P (2013) Drug nanocrystals in the commercial pharmaceutical development
process. Int J Pharm 453 (1):142-156.
Müller, R. H. 1991. Colloidal carriers for controlled drug delivery and targeting: Modification,
characterization and in vivo distribution . Taylor & Francis: USA
Nafee, N., M. Schneider, K. Friebel, M. Dong, U. F. Schaefer, T. E. Murdter, and C. M.
Lehr (2012) Treatment of lung cancer via telomerase inhibition: Self-assembled nano-
plexes versus polymeric nanoparticles as vectors for 2'-O-Methyl-RNA. Eur J Pharm
Biopharm 80 (3):478-489.
Nangia, S. and R. Sureshkumar (2012) Effects of nanoparticle charge and shape anisotropy on
translocation through cell membranes. Langmuir 28 (51):17666-17671.
NanoMedicine ETP (2005) Vision paper and basis for a strategic research agenda for nano-
medicine. European Technology Platform on NanoMedicine :1-40.
Nilsson, B. and K. N. Ekdahl (2012) Complement diagnostics: Concepts, indications, and
practical guidelines. Clin Dev Immunol 2012:1-11.
Oberdörster, G., A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J.
Carter, B. Karn, W. Kreyling, D. Lai, S. Olin, N. Monteiro-Riviere, D. Warheit, and H.
Yang (2005) Principles for characterizing the potential human health effects from expo-
sure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2 (1):1-35.
Oberdörster, G., E. Oberdörster, and J. Oberdörster (2005) Nanotoxicology: An emerging
discipline evolving from studies of ultrafine particles. Environ Health Perspect 113
(7):823-839.
Olive, P. L. and J. P. Banath (2006) The comet assay: A method to measure DNA damage in
individual cells. Nat Protoc 1 (1):23-29.
Paal, K., J. Muller, and L. Hegedus (2001) High affinity binding of paclitaxel to human serum
albumin. Eur J Biochem 268 (7):2187-2191.
Pardridge, W. M (2003) Blood-brain barrier drug targeting: The future of brain drug develop-
ment. Mol Interv 3 (2):90-105.
Perlstein, B., Z. Ram, D. Daniels, A. Ocherashvilli, Y. Roth, S. Margel, and Y. Mardor (2008)
Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI
monitoring. Neuro Oncol 10 (2):153-161.
Polikarpov, D. M., V. M. Cherepanov, R. R. Gabbasov, M. A. Chuev, I. N. Mischenko, V. A. Korshunov,
and V. Y. Panchenko (2013) Efficiency analysis of clearance of two types of exogenous iron
from the rat brain by Mössbauer spectroscopy. Hyperfine Interactions 218 (1-3):83-88.
Powers, K. W., S. C. Brown, V. B. Krishna, S. C. Wasdo, B. M. Moudgil, and S. M. Roberts (2006)
Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of
nanoscale particles for toxicological evaluation. Toxicol Sci 90 (2):296-303.
Purcell, M., J. F. Neault, and H. A. Tajmir-Riahi (2000) Interaction of taxol with human serum
albumin. Biochim Biophys Acta 1478 (1):61-68.
Puzyn, T., B. Rasulev, A. Gajewicz, X. K. Hu, T. P. Dasari, A. Michalkova, H. M. Hwang, A.
Toropov, D. Leszczynska, and J. Leszczynski (2011) Using nano-QSAR to predict the
cytotoxicity of metal oxide nanoparticles. Nat Nanotechnol 6 (3):175-178.
Quan, L. D., P. E. Purdue, X. M. Liu, M. D. Boska, S. M. Lele, G. M. Thiele, T. R. Mikuls, H.
Dou, S. R. Goldring, and D. Wang (2010) Development of a macromolecular prodrug
for the treatment of inflammatory arthritis: Mechanisms involved in arthrotropism and
sustained therapeutic efficacy. Arthritis Res Ther 12 (5):1-10.